Zealand Pharma Informs of New Sanofi (France) (SAN.PA) Scientific Presentations for Lyxumia® and of Own Presentation of a Novel Zealand Liquid Glucagon Analogue at the American Diabetes Association’s 73rd Scientific Sessions
6/17/2013 9:07:52 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs of a series of data relating to Lyxumia® (lixisenatide), a GLP-1 receptor agonist discovered by Zealand and licensed globally to Sanofi, and of new data on a preclinical Zealand pipeline program to be presented at the American Diabetes Association’s (ADA) 73rd Scientific Sessions taking place on 21-25 June 2013 in Chicago, US. The titles of the presentations follow.
Help employers find you! Check out all the jobs and post your resume.
comments powered by